# HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time
Canonical URL: https://biopharmsignal.com/news/BEAT/heartbeam-to-host-first-quarter-2026-results-conference-call-on-wednesday-may-13-2026-at-4-30-p-m-eastern-time
Ticker: BEAT
Company: HeartBeam
Source: HeartBeam
Published: 2026-04-30 12:31 EST
Original Source URL: https://ir.heartbeam.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-02 11:00 EST — [HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home](https://biopharmsignal.com/news/BEAT/heartbeam-announces-new-peer-reviewed-article-demonstrating-potential-to-help-identify-heart-attack-risk-at-home) — Source: HeartBeam
- 2026-05-13 20:01 EST — [HeartBeam Reports First Quarter 2026 Results](https://biopharmsignal.com/news/BEAT/heartbeam-reports-first-quarter-2026-results) — Source: HeartBeam
- 2026-05-11 12:31 EST — [HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic](https://biopharmsignal.com/news/BEAT/heartbeam-initiates-pilot-study-of-first-on-demand-12-lead-ecg-patch-to-detect-ischemia-outside-the-clinic) — Source: HeartBeam
- 2026-05-07 12:31 EST — [HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice](https://biopharmsignal.com/news/BEAT/heartbeam-expands-commercial-presence-across-four-key-u-s-markets-with-addition-of-premier-concierge-practice) — Source: HeartBeam
- 2026-04-30 12:31 EST — [HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time](https://biopharmsignal.com/news/BEAT/heartbeam-to-host-first-quarter-2026-results-conference-call-on-wednesday-may-13-2026-at-4-30-p-m-eastern-time) — Source: HeartBeam
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)